AnHorn Medicines
AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability
AH-001; AI-designed drug; Phase I clinical trial; safety; tolerability; androgenetic alopecia; protein degrader; AnHorn Medicines; generative AI; hair loss